Biotrial Announces New Head of Data Management
Biotrial, a CRO for early phase clinical trials, today announced that Monique Duguépéroux-Klocke has joined the company as its new Head of Data Management.
Rennes, France - November 15th, 2008
Since 1989 Biotrial has provided consistent and reliable clinical data management for in-house clinical trials, as well as complex global clinical studies. From CRF design, data entry, database design, data validation, statistics and consulting, to name a few, Biotrial’s experience includes a wide range of therapeutic areas.
Monique Duguépéroux-Klocke brings over 15 years of experience in the field of clinical research. After leaving a well-known CRO (PAREXEL in Berlin) she worked for over 10 years at one of the top French pharmaceutical companies: Servier Laboratories, as head of the Data Management, Outsourcing Department.
“We are really excited about these new changes in Biotrial’s Data Management department,” said Isabelle Cimarosti, Director of Biometrics Department. “Monique Duguépéroux-Klocke’s arrival attests to our growth and reinforces our position as a global service provider.”
Her responsibilities at Biotrial include overseeing the department’s activity and monitoring its constant growth with thorough training, recruitment and technical means. In the near future, one of her missions will be to answer client needs for data management in Phase III studies in addition to evolving Biotrial’s EDC system. Ms. Duguépéroux-Klocke holds a Master's Degree in Chemistry, and has been a member of the Data Management Biomedical Association since 1998.
Jean-Marc Gandon, Biotrial CEO, commented: “Mrs Duguépéroux-Klocke is a valuable addition to our management team. Her vast experience and her extensive background will be a great asset to the company and to our clients. With over 130 projects handled last year, the biometrics activity is in constant growth. Our team of Database Programmers and Designers, Coding Specialists, Data Entry Operators, and Data Management Project Leaders are excited about this new arrival and see it as an opportunity to continue the development of this activity within the wide range of quality clinical services offered by Biotrial.”
Philippe L'Hostis who was previously heading this department will now be heading the Biotrial ECG and Imaging Central Laboratory activities.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
